Open AccessSwiss Science Concentrates
Author(s) -
Caroline D. Bösch,
Markus Probst,
Yuliia Vyborna,
Mykhailo Vybornyi,
Simon M. Langenegger,
Robert Häner
Publication year - 2015
Publication title -
chimia
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 55
eISSN - 2673-2424
pISSN - 0009-4293
DOI - 10.2533/chimia.2015.710
Subject(s) - biopharmaceutical , biochemical engineering , computer science , bench to bedside , engineering ethics , business , microbiology and biotechnology , nanotechnology , data science , risk analysis (engineering) , engineering , biology , medicine , medical physics , materials science
Three-dimensional (3D) cell culture technology captures the market! Driving forces include an increase in cancer worldwide, but also reinforced research for biopharmaceutical products to cure diseases and to reduce animal experiments. The challenge now is to translate in vitro assays into relevant in vivo outcomes. At the TEDD Annual Meeting, selected experts explored this problem and discussed how to move 3D cell cultures from bench to practice.